相关实验视频

Updated: May 28, 2025

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel

Published on: May 14, 2018

一个随机的第二阶段试验,纳布-帕克利塔塞尔与或没有米费普里斯用于晚期三阴性乳腺癌

Nan Chen¹, Margarite Matossian¹, Poornima Saha²

¹Department of Medicine Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA.

Breast cancer research and treatment

|February 10, 2025

概括

将米费普里斯顿添加到纳布-帕克利塔塞尔并没有改善晚期三阴性乳腺癌 (TNBC) 患者的结果. 组合疗法显示增加了中性质减退,但通常耐受良好,因此需要进一步的生物标志物驱动研究.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

葡萄糖皮质体受体 (GR) 活性与晚期三阴性乳腺癌 (TNBC) 的化学抵抗有关.
临床前模型表明,使用像米费普里斯这样的药物可以增强TNBC中对标素的疗效.

研究的目的:

评估是否用GR抗剂米费普里斯顿进行预治疗,可以改善NAB-PACLITAXEL在晚期TNBC患者的疗效.
评估GR对抗对无进展生存率 (PFS) 和反应率的影响.

主要方法:

一个随机试验涉及29名患有晚期TNBC的患者,比较NAB-PACLITAXEL与或没有MIFEPRISTONE.
米费普里斯在纳布-帕克利塔塞尔剂量注射之前和当天口服.
主要终点是PFS;次要终点包括响应率和GR表达相关性.

主要成果:

添加米费普里斯并没有显著改善PFS (3.0个月 vs 3.0个月) 或整体反应率 (23% vs 31.5%).
发现了改善整体生存率的趋势,这可能受到一个长期响应者的影响.
在组合手臂中出现了3级中性质减退和发烧性中性质减退;其他毒性是可比的.

结论:

这项研究不足以证明米费普里斯加纳布-帕克利塔塞尔在高级TNBC中具有显著的益处.
虽然通常耐受性很好,但这种组合显示出更高的中性衰竭率.
建议对生物标志物进行进一步的研究,以确定在TNBC治疗中可能受益于GR调节器的患者.

关键词:

临床试验临床试验是指临床试验的临床试验.葡萄糖皮质类受体受体在HER2-乳腺癌.这就是米费普里斯顿.纳布-帕克利塔塞尔 (Nab-paclitaxel) 的使用情况

更多相关视频

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

相关概念视频

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...